Alnylam Pharmaceuticals AI Price Prediction

Financial Performance

The financial performance of Alnylam Pharmaceuticals has shown some negative trends in the last quarter. Revenue was reported at $500.9M, showing a decrease by -24.1% from the previous quarter. Gross profit also decreased by -29.8%, standing at $415M, and operating income showed a significant drop of -258.2%, with a loss of -$76.9M. The EBITDA ratio was negative at -0.12, indicating that operating expenses are higher than its earnings.

Stock Price

The stock price is currently trading at $255.28, which shows an increase of 4% in the last month and an impressive growth of 32% year over year compared to the stock's 200-day moving average of $226.56. However, it's important to note that the PE ratio is quite high at -97.44 and the EPS stands at -2.62, suggesting potential overvaluation.

Alternative Data Signals

In terms of alternative data signals, web traffic for Alnylam Pharmaceuticals has slightly decreased by -5.3% month over month but still maintains a decent volume with approximately 55958 visitors per month which indicates sustained interest in the company's activities or products/services among internet users.

The number of job openings has decreased both monthly (-4.3%) and yearly (-22%), possibly indicating restructuring or cost-saving measures within the company.

About two-thirds (66%) employees report having a positive business outlook which is up by +3% from last month but down yearly by -12%. This could suggest mixed sentiments about future prospects within the organization.

Social media followership on Twitter (+1%), Instagram (+38.6%), and Facebook (+124.8%) have all increased over the last 90 days, indicating growing public interest or engagement with the company.

Conclusion

The analysis of Alnylam Pharmaceuticals' stock performance is neutral to slightly bullish due to positive year-over-year stock price growth and social media engagement but tempered by recent declines in financial performance indicators and employee business outlook.